Follow
Ajjai Alva
Ajjai Alva
Verified email at umich.edu - Homepage
Title
Cited by
Cited by
Year
Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8
L Yu, A Alva, H Su, P Dutt, E Freundt, S Welsh, EH Baehrecke, ...
Science 304 (5676), 1500-1502, 2004
15432004
Integrative clinical genomics of metastatic cancer
DR Robinson, YM Wu, RJ Lonigro, P Vats, E Cobain, J Everett, X Cao, ...
Nature 548 (7667), 297-303, 2017
7722017
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
J Yu, MD Green, S Li, Y Sun, SN Journey, JE Choi, SM Rizvi, A Qin, ...
Nature medicine 27 (1), 152-164, 2021
5132021
Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma
TK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, ...
New England Journal of Medicine 385 (8), 683-694, 2021
4822021
Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer
YM Wu, M Cieślik, RJ Lonigro, P Vats, MA Reimers, X Cao, Y Ning, ...
Cell 173 (7), 1770-1782. e14, 2018
4702018
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
3922021
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
3772020
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ...
Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022
3142022
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, ...
Cancer 126 (18), 4156-4167, 2020
2402020
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer …
KJ Pienta, MA Gorin, SP Rowe, PR Carroll, F Pouliot, S Probst, ...
The Journal of urology 206 (1), 52-61, 2021
2212021
NCCN guidelines insights: kidney cancer, version 2.2020: featured updates to the NCCN guidelines
RJ Motzer, E Jonasch, MD Michaelson, L Nandagopal, JL Gore, S George, ...
Journal of the National Comprehensive Cancer Network 17 (11), 1278-1285, 2019
2062019
Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a …
KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ...
JAMA oncology 4 (10), 1344-1351, 2018
1962018
NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines
RJ Motzer, E Jonasch, S Boyle, MI Carlo, B Manley, N Agarwal, A Alva, ...
Journal of the National Comprehensive Cancer Network 18 (9), 1160-1170, 2020
1952020
Bladder cancer treatment response assessment in CT using radiomics with deep-learning
KH Cha, L Hadjiiski, HP Chan, AZ Weizer, A Alva, RH Cohan, EM Caoili, ...
Scientific reports 7 (1), 8738, 2017
1892017
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
SK Pal, C Tangen, IM Thompson, N Balzer-Haas, DJ George, DYC Heng, ...
The Lancet 397 (10275), 695-703, 2021
1852021
Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response
Y Zhang, SP Narayanan, R Mannan, G Raskind, X Wang, P Vats, F Su, ...
Proceedings of the National Academy of Sciences 118 (24), e2103240118, 2021
1602021
Rationale and design of the targeted agent and profiling utilization registry study
PK Mangat, S Halabi, SS Bruinooge, E Garrett-Mayer, A Alva, ...
JCO precision oncology 2, 1-14, 2018
1592018
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised …
T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ...
The lancet oncology 23 (9), 1133-1144, 2022
1452022
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
AM Udager, TY Liu, SL Skala, MJ Magers, AS McDaniel, DE Spratt, ...
Annals of Oncology 27 (9), 1706-1712, 2016
1352016
Autophagy in human tumors: cell survival or death?
AS Alva, SH Gultekin, EH Baehrecke
Cell Death & Differentiation 11 (9), 1046-1048, 2004
1352004
The system can't perform the operation now. Try again later.
Articles 1–20